• 4μ8C: Precision Unfolded Protein Response Inhibitor Workflow

  2026-06-19

  4μ8C (7-hydroxy-4-methyl-2-oxochromene-8-carbaldehyde) delivers selective, non-cytotoxic inhibition of IRE1α RNase, enabling cancer and ER stress research with clarity and reproducibility. This guide translates recent mechanistic insights and real-world troubleshooting into actionable workflows for advanced ER stress assays.

• PDK4-IN-1 Hydrochloride: Precision Pyruvate Dehydrogenase Ki

  2026-06-19

  PDK4-IN-1 hydrochloride from APExBIO empowers researchers to modulate mitochondrial energy metabolism with unmatched selectivity and potency. This guide translates breakthrough findings into actionable protocols and advanced troubleshooting tips for metabolic, cardiac, and tumor research models.

• Cholesterol in Membrane Biophysics: Mechanistic Insights and

  2026-06-18

  Explore cholesterol as the principal sterol and its critical biophysical role in membrane research. This article delivers mechanistic depth, advanced assay guidance, and new perspectives for scientists leveraging APExBIO's high-purity cholesterol.

• Foretinib (GSK1363089): Advancing Multikinase Cancer Researc

  2026-06-18

  Explore the mechanistic insights and translational impact of Foretinib (GSK1363089), a multikinase inhibitor targeting VEGFRs and Met. This article blends molecular rationale, advanced in vitro evaluation strategies, and practical workflow guidance for researchers aiming to model and inhibit tumor growth, motility, and metastasis. Learn how refined viability metrics and robust protocols, supported by recent dissertation findings and real-world scenarios, deliver actionable value beyond standard product listings.

• Anlotinib Hydrochloride: Transforming Translational Cancer R

  2026-06-17

  Explore how Anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, advances angiogenesis research and translational strategy. This article integrates mechanistic insights, validated anti-angiogenic protocols, and recent clinical findings—including its use in IADSRCT—to guide researchers in leveraging its selectivity and safety profile for impactful cancer workflows.

• Thrombin as a Trypsin-like Serine Protease: Applied Workflow

  2026-06-17

  Harness the precision and purity of APExBIO’s thrombin B chain fragment for advanced fibrin matrix modeling, angiogenesis assays, and translational vascular studies. This guide details protocol enhancements, troubleshooting tactics, and practical insights to unlock reliable, reproducible results in hemostasis and endothelial research.

• Olaparib (AZD2281): Molecular Insights and Assay Design for

  2026-06-16

  Explore how Olaparib (AZD2281) advances precision DNA damage response assays and BRCA-associated cancer therapy. This article delivers a molecular-level perspective, integrating phase separation dynamics and experimental best practices for translational oncology.

• Pexmetinib (ARRY-614): Applied Protocols for Cytokine Inhibi

  2026-06-16

  Pexmetinib (ARRY-614) unlocks next-generation workflows for precise inhibition of cytokine synthesis and advanced modulation of p38 MAPK signaling pathways. This guide translates recent dual-action kinase insights into actionable protocols and troubleshooting strategies, supporting research in inflammation and hematologic malignancies.

• Clozapine N-oxide for Precision Neuronal Modulation Workflow

  2026-06-15

  Clozapine N-oxide (CNO) empowers neuroscience researchers to non-invasively and reversibly manipulate discrete neuronal populations with unmatched specificity. This article translates the latest advances in chemogenetic actuator use, featuring DREADDs, into actionable protocols with troubleshooting guidance and highlights novel regional targeting innovations.

• Phase Separation of FUS with PARylated PARP1: Regulation by

  2026-06-15

  This study reveals how polyamines, divalent metal cations, and the branching architecture of poly(ADP-ribose) (PAR) govern the phase separation of the DNA repair protein FUS with PARylated PARP1. The findings provide new mechanistic insight into the assembly of biomolecular condensates in the DNA damage response, with potential implications for targeted cancer research and assay development.

• EV-Transferred ACLY Drives TAM Differentiation in HCC Progre

  2026-06-14

  This study reveals that hepatocellular carcinoma (HCC) cells secrete extracellular vesicles containing ATP-citrate lyase (ACLY), which are internalized by monocytes and trigger their differentiation into immunosuppressive tumor-associated macrophages (TAMs). The findings uncover a metabolic axis that promotes HCC progression and suggest new strategies for enhancing immunotherapy by targeting EV-mediated enzyme transfer.

• Transmissible H-Aggregated NIR-II Fluorophores for Enhanced

  2026-06-13

  Yu et al. (2023) present a lipid nanosystem that enables NIR-II fluorophore H-aggregation transfer to tumor cell membranes, improving photothermal therapy and synergistic chemotherapeutic delivery. This strategy advances integrated cancer diagnosis and treatment by stabilizing photothermal conversion and targeted drug release.

• BIBR 1532: Advancing Telomerase Inhibition for Translational

  2026-06-12

  This thought-leadership article explores the strategic and mechanistic value of BIBR 1532, a selective telomerase inhibitor, for translational oncology researchers. Integrating evidence from telomere biology, leukemia and solid tumor models, and the latest combinatorial strategies, the article provides actionable guidance for designing robust telomerase activity and apoptosis assays. Distinct from generic overviews, it critically positions BIBR 1532 within the evolving landscape of telomere-targeted therapeutics, bridging recent advances with practical protocol recommendations and a forward-thinking outlook.

• Imatinib Hydrochloride: Optimizing Tyrosine Kinase Inhibitio

  2026-06-12

  Imatinib hydrochloride (STI571 hydrochloride) empowers translational oncology research with precise, multi-targeted tyrosine kinase inhibition, enabling robust modeling of CML and GIST signaling pathways. This guide distills the latest dual-action inhibitor insights, advanced protocol enhancements, and troubleshooting strategies for maximizing data reliability and experimental impact.

• Myriocin as a Serine Palmitoyltransferase Inhibitor: Applied

  2026-06-11

  Myriocin, a gold-standard serine palmitoyltransferase inhibitor, empowers researchers to dissect sphingolipid metabolism, modulate metabolic signaling, and interrogate cell proliferation with precision. This guide details advanced workflows, protocol enhancements, and troubleshooting strategies that maximize reproducibility and impact in oncology, immunology, and metabolic research.

8364 records 8/558 page Previous Next First page 上5页 678910 下5页 Last page